Genentech Inc. is fighting a patent challenge to its hemophilia A treatment Hemlibra in the court of public opinion in addition to in front of a US federal judge. The firm has posted an open letter to the hemophilia community to both reassure people that Hemlibra (emicizumab-kxwh) would remain available in the near-term and to denounce Shire PLC for seeking a court order to prevent all but a limited group of patients from having access to the product.
"We are writing this letter because we value transparency. The hemophilia community has fought hard to preserve access to healthcare...